Neural Biomarkers in Fragile X Syndrome

NCT06957054 | Completed

• 1 other identifier: CTH-CTH120-EXP-01
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this non-interventional test /re-test study is to assess neural biomarkers in adult subjects with Fragile X syndrome compared to those measured in a population of typically developing adults

Conditions

Fragile X Syndrome (FXS); Neurotypical Adults

Keywords

Fragile X Syndrome; FXS; Fragile X; Neurodevelopmental Disorders; Central Nervous System Diseases; Intellectual Disability; Neurobehavioral Manifestations; Genetic Diseases, X-Linked; Congenital Abnormalities; Orphan Diseases; Rare Diseases; Neural biomarkers

Outcome Measures

Primary Outcomes (32)

• Cognitive profile of FXS patients compared to neurotypical subjects using the NIH-TCB-ID Toolbox

  The NIH-Toolbox Cognitive Battery for Intellectual Disabilities (NIH-TCB-ID) provides a reliable, validated and standardized measure (composite scores) that can be used as efficacy endpoints in clinical studies in patients with neurodevelopmental disorders from 3 to 85 years old. The Fluid Cognition composite score of the NIH Toolbox cognitive battery combines the scores of five tests assessing the following cognitive domains: i) Cognitive flexibility, ii) Inhibitory control and visual attention, iii) Episodic memory, iv) Processing speed and v) Working memory.

  Day 1 and Day 28 (± 3 days)

• Neural oscillations using Electroencephalography (EEG)

  Multichannel EEG will be recorded using a mobile wireless helmet for high precision EEG monitoring. In total, 20 EEG channels will be used to capture brainwave activity. The EEG test contains three well differentiated sections: auditory oddball, resting-state (eyes open and eyes closed) and auditory steady-state response (ASSR). Before starting the auditory oddball, the subject will conduct a training section (40 seconds) to present the type of sounds and to check that they have understood the task by practicing it.

  Day 1

• Point of gaze using eye tracking

  Eye tracking technology will be used to record X and Y coordinates of eye position and pupil diameter. Stimuli will consist on 60 coloured photographs of adult human faces (equal numbers of males and females; different races and ethnicities), each face exhibiting a calm, happy, or fearful expression, and 60 scrambled versions of the face images. Testing will be conducted in a quiet room with the lights turned off. Each trial will start with presentation of a scrambled face image for 1 s followed immediately by its matched face image for 3 s. An inter-trial interval (ITI) containing a uniform grey screen will be shown for 0.5, 1, or 2 s, randomly determined. The order of face presentation will be pseudorandomized and each eye tracking session will last approximately 6 min.

  Day 1 and Day 28 (± 3 days)

• Behavior troubles of the FXS patients compared to neurotypical subjects using the Aberrant Behavior Checklist (ABC)

  Standardized rating scale used for assessing problematic behavior of individuals with developmental disabilities. The questionnaire explores problem behaviors across 5 domains: Irritability (15 items), Lethargy/Socially Withdrawal (16 items), Stereotypy Behavior (7 items), Hyperactivity/Noncompliance (16 items), Inappropriate Speech (4 items). Each item is scored as 0 (never a problem), 1 (slight problem), 2 (moderately serious problem), or 3 (severe problem). For the present study the total score for each of the 5 domains or subscales will be calculated and used for the analyses, as a good measure of the psychiatric symptom and behavioral disturbance profile. In all cases, higher scores in the mentioned subscales and total score indicated a greater presence and severity of behavioral problems: Agitation \[0-45\]; Lethargy/Social Withdrawal \[0-48\]; Stereotypic Behavior \[0-21\]; Hyperactivity/Noncompliance \[0-48\] and Inappropriate Speech \[0-12\].

  ≤ 1 month prior to Day 1

• Adaptative functioning using the Vineland Adaptive Behaviour Scale (VABS-3)

  The Vineland Adaptative Behaviour Scale 3 (VABS-3) is a psychometric instrument used in child and adolescent clinical psychology for the assessment of individuals with different types of developmental delays, regarding an adaptive level of functioning by standardized interview of the person or their caregiver through their activities of daily living such as walking, talking, getting dressed, going to school, preparing a meal, etc. Three domains explore communication, socialization and daily living, which correspond to the 3 domains of adaptive functioning recognized by the American Association on Intellectual and Developmental Disabilities.

  ≤ 1 month prior to Day 1

• Clinician-rated global functioning using the Clinical Global Impression (CGI)

  The Clinical Global Impression Scale (CGI) comprises two companion one-item measures evaluating the following: 1. Severity of Psychopathology (Clinical Global Impression-Severity (CGI-S) Scale): establishes the baseline illness status and rates illness severity on a 7-point scale \[range 0 to 7\]: 1 for not at all ill; 2 for borderline illness; 3 for mild illness; 4 for moderately ill; 5 for very ill; 6 for severely ill; 7 among the most severe patients; and 2. Change from the Initiation of Treatment (Clinical Global Impression-Improvement (CGI-I) Scale): rates how much the subject's illness has improved or worsened relative to the baseline state (CGI-S) on a 7-point scale \[range -7 to 7\]: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.

  ≤ 1 month prior to Day 1 and Day 28 (± 3 days)

• Stress biomarkers of the FXS patients compared to neurotypical subjects measured by cortisol concentrations in hair (occipital area)

  Hair cortisol analysis characterizes chronic stress as a risk factor for chronic illness progression and is known as a biomarker of the effectiveness of stress reduction interventions. Approximately 3 cm of occipital hair will be collected at the Screening visit for the determination of cortisol concentrations \[range 2.5 - 97.5 pg/mg\].

  ≤ 1 month prior to Day 1

• Biorhythm characteristics of FXS patients compared to neurotypical subjects determining vitamin D (25-Hydroxy) concentrations in serum

  Vitamin D concentrations are also useful due to lack of sunlight exposure is the primary reason for the worldwide epidemic of vitamin D deficiency. The lack of sunlight exposure is involved in serotonin and melatonin production. Venous blood samples will be collected by individual venepuncture or via an indwelling catheter to measure vitamin D (25-Hydroxy) concentrations in serum \[25 - 150 ng/mL\].

  Day 1 and Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects determining 24h urine cortisol concentrations

  The activation of the Hypothalamic Pituitary Adrenal (HPA) axis leads to the synthesis and release of cortisol, a glucocorticoid hormone that peaks in the early morning hours. 24-hour urine samples will be collected before Visit 1 and Visit 2 for the determination of cortisol concentrations \[range 11.5 - 102.0 µg/24h\].

  Day 1 and Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using sleep diaries

  Sleep schedule will be assessed by using sleep diaries to record the quality and quantity of sleep. A sleep diary allows recording when the subject goes to bed, when the subject wakes up during the night and when the subject wakes up in the morning. This will help to understand the sleep pattern and how much sleep the subject gets. It will also show how often the subject has interrupted sleep.

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: number of days

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the number of days \[days\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: percentage of wear

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the percentage of wear \[%\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: total steps

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the total steps \[steps\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: steps per day

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the steps per day \[steps/day\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: average of energy expenditure

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the average of energy expenditure \[kcal/day\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: percentage of sedentary physical activity

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the percentage of sedentary physical activity \[%\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: percentage of light physical activity

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the percentage of light physical activity \[%\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: percentage of moderate physical activity

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the percentage of moderate physical activity \[%\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: percentage of vigorous physical activity

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the percentage of vigorous physical activity \[%\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: percentage of very vigorous physical activity

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the percentage of very vigorous physical activity \[%\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: bedtime

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the bedtime \[hh:mm\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: wake-up time

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the wake-up time \[hh:mm\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: mean time in bed

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the mean time in bed \[minutes\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: total mean sleep time

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the total mean sleep time \[minutes\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: sleep efficiency

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the sleep efficiency \[%\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: wake after sleep onset

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the wake after sleep onset \[minutes\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: average of awakening

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the average of awakening \[awakes\].

  From Day 1 to Day 28 (± 3 days)

• Biorhythm characteristics of FXS patients compared to neurotypical subjects using actigraphy: hours spent awake at night

  Sleep-wake rhythms will be assessed using a wearable actigraph which will register the hours spent awake at night \[minutes\].

  From Day 1 to Day 28 (± 3 days)

• Quality of life of the FXS patients compared to neurotypical subjects using the Paediatric Quality of Life Inventory (PedsQL)

  Health-related quality of life (HRQoL) is a multidimensional concept involving physical, psychological, social, and cognitive aspects of life. Individuals with Fragile X syndrome (FXS) experience a life-long disorder that impacts the HRQoL of the affected individual and their family. HRQoL has been correlated with established measures of functioning in FXS using the: i) Cognitive Functioning Scale \[0-100\], ii) Quality of Life Scale, which is composite of the following items: Physical health and activities \[0-32\], Emotional state \[0-20\], Social activities \[range 0-20\], School activities \[0-20\]; and iii) Family impact scale, which is composite of the following items: Physical health and activities \[0-24\], Emotional state \[0-20\], Social activities \[0-16\], Cognitive function \[0-20\], Communication \[0-12\], Preoccupation \[0-20\], Daily activities \[0-12\] and Family relationships \[0-20\].

  ≤ 1 month prior to Day 1

• Quality of sleep of the FXS patients compared to neurotypical subjects using Pittsburgh sleep quality index (PSQI)

  The Pittsburgh sleep quality index (PSQI) consists in a self-report questionnaire that assesses sleep quality and quantity. The 19-item self-report questionnaire yields 7 component scores: i) subjective sleep quality \[0-3\], ii) sleep latency \[0-3\], ii) duration of the sleep \[0-3\], iii) habitual sleep efficiency \[0-3\], iv) sleep disturbances \[0-3\], v) use of sleeping medication \[0-3\], and vi) daytime dysfunction \[0-3\]. There are five additional questions that are completed by a bed partner if there is one.

  Day 1 and Day 28 (± 3 days)

• FMRP protein in peripheral blood of FXS patients in peripheral blood compared to neurotypical subjects

  Venous blood samples will be obtained by extraction of peripheral blood from participants in a EDTA tube. The levels of FMRP in the FMR1 gene will be reported as a relative value of the mean levels calculated for control \[range 0-1\].

  ≤ 1 month prior to Day 1

• miRNA profile of FXS patients in plasma compared to neurotypical subjects

  Venous blood samples will be obtained by extraction of peripheral blood from participants. For the determination of the miRNomic profile, 200 μL of human plasma will be processed using Plasma/Serum miRNeasy Serum/Plasma kit to extract RNA enriched in small RNAs.

  Day 1 and Day 28 (± 3 days)

Study Arms (2)

Group 1

Fragile X syndrome

Other: Any

Group 2

Typically Developing Subjects

Other: Any

Interventions

Any OTHER

Any

Group 1; Group 2

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Fragile X syndrome adult patients compared to neurotypical adults

You may qualify if:

• Clinical and molecular diagnosis of Fragile X syndrome (\> 200 CGG repeats in the promoter region of the FMR1 gene).
• Legal representative understands and accepts the study procedures. If only one parent signs, he/she should confirm that the other parent does not object to the patient's participation in the research project.
• Subject assenting and/or willing to participate.
• Signed informed consent by a legal representative before any study-mandated procedure.
• Subject is independently mobile and has sufficient vision and hearing to participate in study evaluations. They must be able to be understood most of the time and must not use other forms of communication, signs, symbol boards or devices as their primary form of communication.
• Subjects must have a parent, or other reliable caregiver, who agrees to accompany the subject to all study visits, provide information about the subject as required by the protocol, and ensure compliance with study tests.
• Subjects are expected to complete all procedures scheduled during the study visits.

You may not qualify if:

• Personal history of infantile spasms/convulsions/epilepsy, severe head trauma or CNS infections (e.g. meningitis), with the exception of infantile febrile seizures.
• Substance use disorder according to the DSM-5 criteria.
• Epileptiform abnormalities (excluding isolated sharp waves and beyond those expected for age).
• Any life-threatening disease.
• Any other clinically relevant concomitant disease or condition or finding at screening that in the judgment of the investigator could interfere with, the treatment thereof might interfere with, the conduct of the study and related procedures and/or might bias the study results interpretation, or could jeopardize the subject's safety.
• Any clinically significant findings in physical examination including vital signs.
• Any prescription or over-the-counter drug (except occasional use of paracetamol) in the last 2 weeks before screening.
• Abstinence for any drug abuse 72 hours prior to the screening visit and the observation days, except for nicotine (24 hours).
• Able to read Spanish and/or Catalan and to adhere to the study requirements.
• Signed informed consent prior to any study-mandated procedure.
• Life-time clinically significant cardiovascular, renal, pulmonary, hepatic, onco-haematological, endocrine, gastrointestinal, mental or neurological disease.
• Any other clinically relevant concomitant disease or condition or finding at screening that in the judgment of the investigator could interfere with, the treatment thereof might interfere with, the conduct of the study and related procedures and/or might bias the study results interpretation, or could jeopardize the subject's safety.
• Any clinically significant findings in physical examination including vital signs.
• Any prescription or over-the-counter drug (except occasional use of paracetamol) in the last 2 weeks before screening.
• Personal history of infantile spasms/convulsions/epilepsy, severe head trauma or CNS infections (e.g. meningitis), except for infantile febrile seizures.

Sponsors & Collaborators

• Connecta Therapeutics, S.L.: lead
• Hospital del Mar Research Institute (IMIM): collaborator
• Corporacion Parc Tauli: collaborator
• Ministry of Science and Innovation, Spain: collaborator

Study Sites (2)

Hospital del Mar Research Institute (HMRI)

Barcelona, Barcelona, 08003, Spain

Location

Consorci Corporació Sanitaria Parc Taulí. Institut Investigació i Innovació Parc Taulí (I3PT)

Sabadell, Barcelona, 08208, Spain

Location

Related Publications (65)

• Sotoudeh Anvari M, Vasei H, Najmabadi H, Badv RS, Golipour A, Mohammadi-Yeganeh S, Salehi S, Mohamadi M, Goodarzynejad H, Mowla SJ. Identification of microRNAs associated with human fragile X syndrome using next-generation sequencing. Sci Rep. 2022 Mar 23;12(1):5011. doi: 10.1038/s41598-022-08916-4.

  PMID: 35322102 BACKGROUND

• Couto RR, Kubaski F, Siebert M, Felix TM, Brusius-Facchin AC, Leistner-Segal S. Increased Serum Levels of miR-125b and miR-132 in Fragile X Syndrome: A Preliminary Study. Neurol Genet. 2022 Oct 26;8(6):e200024. doi: 10.1212/NXG.0000000000200024. eCollection 2022 Dec.

  PMID: 36313066 BACKGROUND

• Lin SL. microRNAs and Fragile X Syndrome. Adv Exp Med Biol. 2015;888:107-21. doi: 10.1007/978-3-319-22671-2_7.

  PMID: 26663181 BACKGROUND

• Daly I, Pichiorri F, Faller J, Kaiser V, Kreilinger A, Scherer R, Muller-Putz G. What does clean EEG look like? Annu Int Conf IEEE Eng Med Biol Soc. 2012;2012:3963-6. doi: 10.1109/EMBC.2012.6346834.

  PMID: 23366795 BACKGROUND

• Castren M, Paakkonen A, Tarkka IM, Ryynanen M, Partanen J. Augmentation of auditory N1 in children with fragile X syndrome. Brain Topogr. 2003 Spring;15(3):165-71. doi: 10.1023/a:1022606200636.

  PMID: 12705812 BACKGROUND

• Kenny A, Wright D, Stanfield AC. EEG as a translational biomarker and outcome measure in fragile X syndrome. Transl Psychiatry. 2022 Jan 24;12(1):34. doi: 10.1038/s41398-022-01796-2.

  PMID: 35075104 BACKGROUND

• Varni JW, Limbers CA. The PedsQL 4.0 Generic Core Scales Young Adult Version: feasibility, reliability and validity in a university student population. J Health Psychol. 2009 May;14(4):611-22. doi: 10.1177/1359105309103580.

  PMID: 19383661 BACKGROUND

• Aman MG, Norris M, Kaat AJ, Andrews H, Choo TH, Chen C, Wheeler A, Bann C, Erickson C. Factor Structure of the Aberrant Behavior Checklist in Individuals with Fragile X Syndrome: Clarifications and Future Guidance. J Child Adolesc Psychopharmacol. 2020 Oct;30(8):512-521. doi: 10.1089/cap.2019.0177. Epub 2020 Aug 3.

  PMID: 32746626 BACKGROUND

• Prosser H, Moss S, Costello H, Simpson N, Patel P, Rowe S. Reliability and validity of the Mini PAS-ADD for assessing psychiatric disorders in adults with intellectual disability. J Intellect Disabil Res. 1998 Aug;42 ( Pt 4):264-72. doi: 10.1046/j.1365-2788.1998.00146.x.

  PMID: 9786440 BACKGROUND

• Shields RH, Kaat AJ, McKenzie FJ, Drayton A, Sansone SM, Coleman J, Michalak C, Riley K, Berry-Kravis E, Gershon RC, Widaman KF, Hessl D. Validation of the NIH Toolbox Cognitive Battery in intellectual disability. Neurology. 2020 Mar 24;94(12):e1229-e1240. doi: 10.1212/WNL.0000000000009131. Epub 2020 Feb 24.

  PMID: 32094241 BACKGROUND

• Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.

  PMID: 2748771 BACKGROUND

• Tottenham N, Tanaka JW, Leon AC, McCarry T, Nurse M, Hare TA, Marcus DJ, Westerlund A, Casey BJ, Nelson C. The NimStim set of facial expressions: judgments from untrained research participants. Psychiatry Res. 2009 Aug 15;168(3):242-9. doi: 10.1016/j.psychres.2008.05.006. Epub 2009 Jun 28.

  PMID: 19564050 BACKGROUND

• Bailey DB Jr, Berry-Kravis E, Wheeler A, Raspa M, Merrien F, Ricart J, Koumaras B, Rosenkranz G, Tomlinson M, von Raison F, Apostol G. Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study. J Neurodev Disord. 2016;8:1. doi: 10.1186/s11689-015-9134-5. Epub 2015 Dec 15.

  PMID: 26855682 BACKGROUND

• Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet. 2000 Jan;66(1):6-15. doi: 10.1086/302720.

  PMID: 10631132 BACKGROUND

• Zafarullah M, Li J, Salemi MR, Phinney BS, Durbin-Johnson BP, Hagerman R, Hessl D, Rivera SM, Tassone F. Blood Proteome Profiling Reveals Biomarkers and Pathway Alterations in Fragile X PM at Risk for Developing FXTAS. Int J Mol Sci. 2023 Aug 30;24(17):13477. doi: 10.3390/ijms241713477.

  PMID: 37686279 BACKGROUND

• Bowling H, Bhattacharya A, Zhang G, Alam D, Lebowitz JZ, Bohm-Levine N, Lin D, Singha P, Mamcarz M, Puckett R, Zhou L, Aryal S, Sharp K, Kirshenbaum K, Berry-Kravis E, Neubert TA, Klann E. Altered steady state and activity-dependent de novo protein expression in fragile X syndrome. Nat Commun. 2019 Apr 12;10(1):1710. doi: 10.1038/s41467-019-09553-8.

  PMID: 30979884 BACKGROUND

• AlOlaby RR, Sweha SR, Silva M, Durbin-Johnson B, Yrigollen CM, Pretto D, Hagerman RJ, Tassone F. Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome. Brain Dev. 2017 Jun;39(6):483-492. doi: 10.1016/j.braindev.2017.01.012. Epub 2017 Feb 24.

  PMID: 28242040 BACKGROUND

• Bekheet MHY, Mansour LA, Elkaffas RH, Kamel MA, Elmonem MA. Serum matrix metalloproteinase-9 (MMP9) and amyloid-beta protein precursor (APP) as potential biomarkers in children with Fragile-X syndrome: A cross sectional study. Clin Biochem. 2023 Nov;121-122:110659. doi: 10.1016/j.clinbiochem.2023.110659. Epub 2023 Oct 4.

  PMID: 37797798 BACKGROUND

• Dionne O, Corbin F. A new strategy to uncover fragile X proteomic biomarkers using the nascent proteome of peripheral blood mononuclear cells (PBMCs). Sci Rep. 2021 Jul 26;11(1):15148. doi: 10.1038/s41598-021-94027-5.

  PMID: 34312401 BACKGROUND

• Zafarullah M, Tassone F. Molecular Biomarkers in Fragile X Syndrome. Brain Sci. 2019 Apr 27;9(5):96. doi: 10.3390/brainsci9050096.

  PMID: 31035599 BACKGROUND

• Hessl D, Glaser B, Dyer-Friedman J, Blasey C, Hastie T, Gunnar M, Reiss AL. Cortisol and behavior in fragile X syndrome. Psychoneuroendocrinology. 2002 Oct;27(7):855-72. doi: 10.1016/s0306-4530(01)00087-7.

  PMID: 12183220 BACKGROUND

• Russell E, Koren G, Rieder M, Van Uum S. Hair cortisol as a biological marker of chronic stress: current status, future directions and unanswered questions. Psychoneuroendocrinology. 2012 May;37(5):589-601. doi: 10.1016/j.psyneuen.2011.09.009. Epub 2011 Oct 4.

  PMID: 21974976 BACKGROUND

• Wright KD, Hickman R, Laudenslager ML. Hair Cortisol Analysis: A Promising Biomarker of HPA Activation in Older Adults. Gerontologist. 2015 Jun;55 Suppl 1(Suppl 1):S140-5. doi: 10.1093/geront/gnu174.

  PMID: 26055775 BACKGROUND

• Prono F, Bernardi K, Ferri R, Bruni O. The Role of Vitamin D in Sleep Disorders of Children and Adolescents: A Systematic Review. Int J Mol Sci. 2022 Jan 27;23(3):1430. doi: 10.3390/ijms23031430.

  PMID: 35163353 BACKGROUND

• Hardiman RL, Bratt A. Hypothalamic-pituitary-adrenal axis function in Fragile X Syndrome and its relationship to behaviour: A systematic review. Physiol Behav. 2016 Dec 1;167:341-353. doi: 10.1016/j.physbeh.2016.09.030. Epub 2016 Oct 5.

  PMID: 27720735 BACKGROUND

• Dueck A, Reis O, Bastian M, van Treeck L, Weirich S, Haessler F, Fiedler A, Koelch M, Berger C. Feasibility of a Complex Setting for Assessing Sleep and Circadian Rhythmicity in a Fragile X Cohort. Front Psychiatry. 2020 May 14;11:361. doi: 10.3389/fpsyt.2020.00361. eCollection 2020.

  PMID: 32477175 BACKGROUND

• Farzin F, Scaggs F, Hervey C, Berry-Kravis E, Hessl D. Reliability of eye tracking and pupillometry measures in individuals with fragile X syndrome. J Autism Dev Disord. 2011 Nov;41(11):1515-22. doi: 10.1007/s10803-011-1176-2.

  PMID: 21267642 BACKGROUND

• Klusek J, Moser C, Schmidt J, Abbeduto L, Roberts JE. A novel eye-tracking paradigm for indexing social avoidance-related behavior in fragile X syndrome. Am J Med Genet B Neuropsychiatr Genet. 2020 Jan;183(1):5-16. doi: 10.1002/ajmg.b.32757. Epub 2019 Aug 16.

  PMID: 31418535 BACKGROUND

• Ethridge LE, Pedapati EV, Schmitt LM, Norris JE, Auger E, De Stefano LA, Sweeney JA, Erickson CA. Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership Fragile X Syndrome. Res Sq [Preprint]. 2024 Jan 18:rs.3.rs-3849272. doi: 10.21203/rs.3.rs-3849272/v1.

  PMID: 38313274 BACKGROUND

• Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Warren ST. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009 Oct;85(4):503-14. doi: 10.1016/j.ajhg.2009.09.007.

  PMID: 19804849 BACKGROUND

• Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. Am J Med Genet A. 2014 Jul;164A(7):1648-58. doi: 10.1002/ajmg.a.36511. Epub 2014 Apr 3.

  PMID: 24700618 BACKGROUND

• Tassone F, Iong KP, Tong TH, Lo J, Gane LW, Berry-Kravis E, Nguyen D, Mu LY, Laffin J, Bailey DB, Hagerman RJ. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012 Dec 21;4(12):100. doi: 10.1186/gm401. eCollection 2012.

  PMID: 23259642 BACKGROUND

• Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med. 2001 Sep-Oct;3(5):359-71. doi: 10.1097/00125817-200109000-00006.

  PMID: 11545690 BACKGROUND

• Kidd SA, Lachiewicz A, Barbouth D, Blitz RK, Delahunty C, McBrien D, Visootsak J, Berry-Kravis E. Fragile X syndrome: a review of associated medical problems. Pediatrics. 2014 Nov;134(5):995-1005. doi: 10.1542/peds.2013-4301. Epub 2014 Oct 6.

  PMID: 25287458 BACKGROUND

• Rajan-Babu IS, Chong SS. Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders. Genes (Basel). 2016 Oct 14;7(10):87. doi: 10.3390/genes7100087.

  PMID: 27754417 BACKGROUND

• Tassone F. Advanced technologies for the molecular diagnosis of fragile X syndrome. Expert Rev Mol Diagn. 2015;15(11):1465-73. doi: 10.1586/14737159.2015.1101348. Epub 2015 Oct 21.

  PMID: 26489042 BACKGROUND

• Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med. 2009 Dec;57(8):830-6. doi: 10.2310/JIM.0b013e3181af59c4.

  PMID: 19574929 BACKGROUND

• Utari A, Adams E, Berry-Kravis E, Chavez A, Scaggs F, Ngotran L, Boyd A, Hessl D, Gane LW, Tassone F, Tartaglia N, Leehey MA, Hagerman RJ. Aging in fragile X syndrome. J Neurodev Disord. 2010 Jun;2(2):70-76. doi: 10.1007/s11689-010-9047-2. Epub 2010 May 12.

  PMID: 20585378 BACKGROUND

• Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord. 2011 Mar;3(1):57-67. doi: 10.1007/s11689-010-9067-y. Epub 2010 Dec 3.

  PMID: 21475730 BACKGROUND

• Bartholomay KL, Lee CH, Bruno JL, Lightbody AA, Reiss AL. Closing the Gender Gap in Fragile X Syndrome: Review on Females with FXS and Preliminary Research Findings. Brain Sci. 2019 Jan 12;9(1):11. doi: 10.3390/brainsci9010011.

  PMID: 30642066 BACKGROUND

• Sauna-Aho O, Bjelogrlic-Laakso N, Siren A, Arvio M. Signs indicating dementia in Down, Williams and Fragile X syndromes. Mol Genet Genomic Med. 2018 Sep;6(5):855-860. doi: 10.1002/mgg3.430. Epub 2018 Jul 3.

  PMID: 29971948 BACKGROUND

• McLennan Y, Polussa J, Tassone F, Hagerman R. Fragile x syndrome. Curr Genomics. 2011 May;12(3):216-24. doi: 10.2174/138920211795677886.

  PMID: 22043169 BACKGROUND

• Bailey DB Jr, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A. 2008 Aug 15;146A(16):2060-9. doi: 10.1002/ajmg.a.32439.

  PMID: 18570292 BACKGROUND

• Pilaz LJ, Lennox AL, Rouanet JP, Silver DL. Dynamic mRNA Transport and Local Translation in Radial Glial Progenitors of the Developing Brain. Curr Biol. 2016 Dec 19;26(24):3383-3392. doi: 10.1016/j.cub.2016.10.040. Epub 2016 Dec 1.

  PMID: 27916527 BACKGROUND

• Danesi C, Achuta VS, Corcoran P, Peteri UK, Turconi G, Matsui N, Albayrak I, Rezov V, Isaksson A, Castren ML. Increased Calcium Influx through L-type Calcium Channels in Human and Mouse Neural Progenitors Lacking Fragile X Mental Retardation Protein. Stem Cell Reports. 2018 Dec 11;11(6):1449-1461. doi: 10.1016/j.stemcr.2018.11.003. Epub 2018 Nov 29.

  PMID: 30503263 BACKGROUND

• Pasciuto E, Ahmed T, Wahle T, Gardoni F, D'Andrea L, Pacini L, Jacquemont S, Tassone F, Balschun D, Dotti CG, Callaerts-Vegh Z, D'Hooge R, Muller UC, Di Luca M, De Strooper B, Bagni C. Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to Synaptic Deficits in Fragile X Syndrome. Neuron. 2015 Jul 15;87(2):382-98. doi: 10.1016/j.neuron.2015.06.032.

  PMID: 26182420 BACKGROUND

• Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci. 2014 Jul 23;34(30):9867-79. doi: 10.1523/JNEUROSCI.1162-14.2014.

  PMID: 25057190 BACKGROUND

• Kashima R, Roy S, Ascano M, Martinez-Cerdeno V, Ariza-Torres J, Kim S, Louie J, Lu Y, Leyton P, Bloch KD, Kornberg TB, Hagerman PJ, Hagerman R, Lagna G, Hata A. Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome. Sci Signal. 2016 Jun 7;9(431):ra58. doi: 10.1126/scisignal.aaf6060.

  PMID: 27273096 BACKGROUND

• Wahlstrom-Helgren S, Klyachko VA. GABAB receptor-mediated feed-forward circuit dysfunction in the mouse model of fragile X syndrome. J Physiol. 2015 Nov 15;593(22):5009-24. doi: 10.1113/JP271190. Epub 2015 Oct 2.

  PMID: 26282581 BACKGROUND

• Gkogkas CG, Khoutorsky A, Cao R, Jafarnejad SM, Prager-Khoutorsky M, Giannakas N, Kaminari A, Fragkouli A, Nader K, Price TJ, Konicek BW, Graff JR, Tzinia AK, Lacaille JC, Sonenberg N. Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep. 2014 Dec 11;9(5):1742-1755. doi: 10.1016/j.celrep.2014.10.064. Epub 2014 Nov 26.

  PMID: 25466251 BACKGROUND

• Wang H, Wu LJ, Kim SS, Lee FJ, Gong B, Toyoda H, Ren M, Shang YZ, Xu H, Liu F, Zhao MG, Zhuo M. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron. 2008 Aug 28;59(4):634-47. doi: 10.1016/j.neuron.2008.06.027.

  PMID: 18760699 BACKGROUND

• Chandana SR, Behen ME, Juhasz C, Muzik O, Rothermel RD, Mangner TJ, Chakraborty PK, Chugani HT, Chugani DC. Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism. Int J Dev Neurosci. 2005 Apr-May;23(2-3):171-82. doi: 10.1016/j.ijdevneu.2004.08.002.

  PMID: 15749243 BACKGROUND

• Boccuto L, Chen CF, Pittman AR, Skinner CD, McCartney HJ, Jones K, Bochner BR, Stevenson RE, Schwartz CE. Decreased tryptophan metabolism in patients with autism spectrum disorders. Mol Autism. 2013 Jun 3;4(1):16. doi: 10.1186/2040-2392-4-16.

  PMID: 23731516 BACKGROUND

• Hanson AC, Hagerman RJ. Serotonin dysregulation in Fragile X Syndrome: implications for treatment. Intractable Rare Dis Res. 2014 Nov;3(4):110-7. doi: 10.5582/irdr.2014.01027.

  PMID: 25606361 BACKGROUND

• Feng Y, Gutekunst CA, Eberhart DE, Yi H, Warren ST, Hersch SM. Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci. 1997 Mar 1;17(5):1539-47. doi: 10.1523/JNEUROSCI.17-05-01539.1997.

  PMID: 9030614 BACKGROUND

• Gholizadeh S, Halder SK, Hampson DR. Expression of fragile X mental retardation protein in neurons and glia of the developing and adult mouse brain. Brain Res. 2015 Jan 30;1596:22-30. doi: 10.1016/j.brainres.2014.11.023. Epub 2014 Nov 20.

  PMID: 25446451 BACKGROUND

• Richter JD, Bassell GJ, Klann E. Dysregulation and restoration of translational homeostasis in fragile X syndrome. Nat Rev Neurosci. 2015 Oct;16(10):595-605. doi: 10.1038/nrn4001. Epub 2015 Sep 9.

  PMID: 26350240 BACKGROUND

• Darnell JC, Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci. 2013 Nov;16(11):1530-6. doi: 10.1038/nn.3379. Epub 2013 Apr 14.

  PMID: 23584741 BACKGROUND

• Bakker CE, Oostra BA. Understanding fragile X syndrome: insights from animal models. Cytogenet Genome Res. 2003;100(1-4):111-23. doi: 10.1159/000072845.

  PMID: 14526171 BACKGROUND

• Banerjee A, Ifrim MF, Valdez AN, Raj N, Bassell GJ. Aberrant RNA translation in fragile X syndrome: From FMRP mechanisms to emerging therapeutic strategies. Brain Res. 2018 Aug 15;1693(Pt A):24-36. doi: 10.1016/j.brainres.2018.04.008. Epub 2018 Apr 10.

  PMID: 29653083 BACKGROUND

• Grigsby J. The fragile X mental retardation 1 gene (FMR1): historical perspective, phenotypes, mechanism, pathology, and epidemiology. Clin Neuropsychol. 2016 Aug;30(6):815-33. doi: 10.1080/13854046.2016.1184652. Epub 2016 Jun 29.

  PMID: 27356167 BACKGROUND

• Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics. 2010 Jul;7(3):264-74. doi: 10.1016/j.nurt.2010.05.005.

  PMID: 20643379 BACKGROUND

• Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB Jr, Moine H, Kooy RF, Tassone F, Gantois I, Sonenberg N, Mandel JL, Hagerman PJ. Fragile X syndrome. Nat Rev Dis Primers. 2017 Sep 29;3:17065. doi: 10.1038/nrdp.2017.65.

  PMID: 28960184 BACKGROUND

• Quartier A, Poquet H, Gilbert-Dussardier B, Rossi M, Casteleyn AS, Portes VD, Feger C, Nourisson E, Kuentz P, Redin C, Thevenon J, Mosca-Boidron AL, Callier P, Muller J, Lesca G, Huet F, Geoffroy V, El Chehadeh S, Jung M, Trojak B, Le Gras S, Lehalle D, Jost B, Maury S, Masurel A, Edery P, Thauvin-Robinet C, Gerard B, Mandel JL, Faivre L, Piton A. Intragenic FMR1 disease-causing variants: a significant mutational mechanism leading to Fragile-X syndrome. Eur J Hum Genet. 2017 Apr;25(4):423-431. doi: 10.1038/ejhg.2016.204. Epub 2017 Feb 8.

  PMID: 28176767 BACKGROUND

• Myrick LK, Nakamoto-Kinoshita M, Lindor NM, Kirmani S, Cheng X, Warren ST. Fragile X syndrome due to a missense mutation. Eur J Hum Genet. 2014 Oct;22(10):1185-9. doi: 10.1038/ejhg.2013.311. Epub 2014 Jan 22.

  PMID: 24448548 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Plasma, urine and hair samples

MeSH Terms

Conditions

Fragile X Syndrome; Neurodevelopmental Disorders; Central Nervous System Diseases; Intellectual Disability; Neurobehavioral Manifestations; Genetic Diseases, X-Linked; Congenital Abnormalities; Rare Diseases

Condition Hierarchy (Ancestors)

X-Linked Intellectual Disability; Neurologic Manifestations; Nervous System Diseases; Sex Chromosome Disorders; Chromosome Disorders; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, Inborn; Heredodegenerative Disorders, Nervous System; Mental Disorders; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Disease Attributes; Pathologic Processes

Study Officials

• Rafael De la Torre Fornell, Pharm, PhD

  Hospital del Mar Research Institute

  PRINCIPAL INVESTIGATOR

• Ana Roche Martínez, MD, PhD

  Consorci Corporació Sanitària Parc Taulí. Institut d'Investigació i Innovació Parc Taulí (I3PT)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 10, 2025
• First Posted: May 4, 2025
• Study Start: December 16, 2024
• Primary Completion: March 20, 2025
• Study Completion: March 20, 2025
• Last Updated: May 4, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

ES (2)